Genomic study aims to boost multiple myeloma survival, treatment
This article was originally published in Scrip
Executive Summary
Survival in multiple myeloma is lengthening due to new therapies and novel agents in the pipeline have the potential to add more years to patients' lives, but researchers and pharmaceuticals companies are looking for the best drug combinations to extend remissions and reduce the need for retreatment.